El Dr. Shlomo Sadoun se une al consejo asesor
15 de abril de 2024
Argent BioPharma Ltd.
Dr. Shlomo Sadoun Joins Argent BioPharma Ltd Advisory Board
Argent BioPharma Ltd (Argén Biofarma o de Empresa), an innovative drug discovery company within the biopharmaceutical sector, is pleased to announce Dr. Shlomo Sadoun has joined Argent BioPharma's advisory board with immediate effect.
Dr. Shlomo Sadoun has over 18 years of experience in the pharmaceutical sector. Dr. Sadoun co-founded and leads SK-Pharma Group, a global pharmaceutical company operating in 18 countries. SK-Pharma specialises in producing and marketing generic, specialty pharma, hybrid generics, and biosimilar pharmaceutical products. Additionally, Dr. Sadoun serves as the CEO of Arphio, an orphan drug company utilising proprietary technology to promote, market, and sell orphan drugs worldwide.
Dr. Sadoun's expertise lies in leveraging technology to redefine business processes. He has established strategic alliances with over 200 innovative companies and launched more than 300 products globally, many of which were pioneering and branded. Dr. Sadoun's adeptness in utilising technological advancements has propelled SK-Pharma to become the fastest-growing pharmaceutical group in Israel and beyond. Dr. Sadoun holds a master's degree in Global Management from Salford University and a Doctorate in Business Administration from the Royal Academy of Economics and Technology in Switzerland, with a focus on public health.
Roby Zomer, Managing Director and CEO of Argent BioPharma, commented: "We are delighted to welcome Dr. Shlomo Sadoun, an esteemed addition to our advisory board. With his wealth of experience and expertise in the pharmaceutical sector, Dr. Sadoun will undoubtedly provide invaluable insights and guidance as we embark on our new strategic direction. His appointment reaffirms our commitment to fostering a diverse and knowledgeable advisory board, dedicated to driving innovation and growth in our Company."
-###-
Autorizado para su divulgación por la junta directiva, para más información, comuníquese con:
Biofarmacia Argenta Roby Zömer CEO y Director Gerente +61 8 6382 3390
| Biofarmacia Argenta Rowan Harland Secretaria de Empresa +61 8 6382 3390 |
Asesores de Relaciones Internacionales y Relaciones Públicas del Reino Unido Asesoría IFC Graham Herring/Tim Metcalfe/Zach Cohen +44 203 934 6630 | UK Brokers Capital de Oberón Aimee McCusker / Adam Pollock +44 203 179 5300 |
Sobre Biofarmacia Argenta
Argent BioPharma is dedicated to meeting unmet medical needs by combining PolyPharmacology and Nanotechnology, aspiring to be a renowned global leader in the biopharmaceutical sector. Our mission centres on researching and developing ground-breaking treatments for worldwide health issues, guided by strategic principles such as pioneering life science advancements, ensuring global access, fostering continuous innovation, and striving for industry leadership.
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.